Latest News

Category: News

See all

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Sweden

News,

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Swedish MPA for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enables healthcare providers in Sweden to offer PSMA-PET imaging using...

Read more

Telix Announces Cardinal Health for Gozellix Commercial Distribution

News,

Telix today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix® (kit for...

Read more

Telix Responds to Recent U.S. Government Actions

ASX, News,

Telix advises that it does not expect any material impact on its business or supply chain as the result of the international trade tariffs levied by the U.S. government, announced...

Read more

Telix Appoints Paul Schaffer as Chief Technology Officer

News,

Telix today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today....

Read more

Anne Whitaker Appointed as Non-Executive Director

ASX, News,

Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April...

Read more

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

Clinical, News,

Telix today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the...

Read more

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

ASX, News,

Telixtoday announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide...

Read more

Telix at EAU25

News,

Join Telix this week at Europe’s largest urological event, the 40th Annual European Association of Urology Congress (EAU25) being held in Madrid, Spain. Telix’s Phase 3 ProstACT Global study of lead...

Read more

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in The Netherlands

News,

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by MEB for the detection and...

Read more

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

ASX, News,

Telix today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘ANVISA’) has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) the Company’s...

Read more